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Abstract 
 
Background: To compare the efficacy and safety of 
oral versus vaginal administration of Misoprostol for 
induction of labour at term. 
Methods:  In this interventional study primigravida 
were assigned in two groups; A and B, using non-
probability convenient sampling technique. Group-A 
(n=50) had Misoprostol orally, while group-B (n=50) 
received the drug by vaginal route. Dosage was 100 µg four 
hours apart in group-A and six hours apart in group-B. 
Maximum of four doses were given. Main outcome 
measures of study were labour-induction interval, labour-
delivery interval, mode of delivery, neonatal outcome and 
feto-maternal complications.  
 
Results: The mean dosage requirement for induction of 
labour in groups A and B was 2.1±1.1 and 2.4±1.8 (p-0.23) 
respectively. Mean labour-induction interval in group A 
and B were 7.5±4.2 and 7.3±4.1 (p-0.87) hours respectively, 
which is not significant statistically. Mean labour delivery 
interval was shorter in vaginal group (4.9±2.7 hours) versus 
oral group(6.0±2.2) hours (p-0.04). Need for Oxytocin 
augmentation was less in vaginal group (21%) versus oral 
group (68%) (p-0.009). There was no statistical difference 
between the groups with respect to mode of delivery and 
neonatal outcome. The incidence of hyper-stimulation was 
similar in both groups. 
Conclusion:Misoprostol is a cost effective alternate for 
induction of labour. Misoprostol through vaginal route 
results in successful cervical ripening, less need for 
oxytocin and shorter time to delivery with acceptable 
safety profile.  
Key words: Induction labour, Misoprostol, 
primigravida, maternal complication, fetal complication. 
 
Introduction 
 
Induction of labour is an important and 
common clinical procedure in obstetrics. Labour 
induction is indicated when the benefits of delivery to 
the mother or fetus outweigh the potential risk of 
continuing the pregnancy. The widespread availability 
of cervical ripening agents has contributed to this 
rising trend but the search for an ideal agent, timing 
and dosage interval to convert an unfavourable cervix 
to one receptive to delivery is an ongoing process. 
PGE2 has been used extensively and effectively for 
ripening cervix and labour initiation. PGE1 
(Misoprostol) is a recently introduced drug for the 
same purpose.1,2 In these days of financial constrains, 
Misoprostol is an economical and effective drug for 
labour induction.  
Misoprostol is well absorbed by oral route, 
with peak plasma concentration achieved earlier and 
higher than vaginal administration, although the 
plasma concentration is detectable for long period by 
vaginal route.3,4 . When used in low doses Misoprostol 
is as effective as vaginal Dinoprostone, with no 
increase in hyper-stimulation. 
 
Patients and Methods 
 
This study was performed in department of 
Gynaecology and Obstetrics, Ittefaq  Hospital Trust, 
Lahore, from June 2008 to May 2009. One hundred 
patients, with indications for induction of labour, at 
term (37- 42weeks) were included . After history and 
clinical examination patients were selected using non-
probability convenient sampling technique. 100 µg of 
Misoprostol was administered through oral and 
vaginal routes, (50 in each group). A preliminary 
admission CTG was done to assess fetal condition. 
Inclusion criteria were women with 
primigravida, singleton pregnancy, vertex 
presentation and gestational age 37- 42 weeks, Bishop 
score less than 5 and a reactive fetal cardiac trace. 
Women with fetal abnormality, intrauterine death, 
were also included in the study. Exclusion criteria 
were multiple gestations, scarred uterus, and 
malpresentation. 
Initially 100 µg of Misoprostol was given 
orally and vaginally. Further doses were repeated four 
hourly in group-A, six hourly in group-B and to a 
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maximum of four doses were given.  
Patients were monitored for uterine 
contraction, fetal heart rate, hyper-stimulation, nausea, 
vomiting, diarrhoea, fever, vaginal bleeding and other 
untoward side effects.  Partograph was maintained. 
CTG was done before induction and after each 
insertion of Misoprostol and then intermittently 
during labour. Requirement for augmentation of 
labour with Oxytocin in either group was also 
recorded. 
Results 
A total of one hundred patients were included 
in this study. Two groups were made with equal 
number of cases in each group. There was no 
significant difference in terms of maternal and 
gestational ages (Table - I).  
The mean dosage for induction of labour in 
group A and B was 2.1±1.1 and 2.4±1.8 (p-0.23) 
respectively. Mean labour-induction interval in group 
A and B was 7.5±4.2 and 7.3±7.4.1 (p-0.87) hours 
respectively which was not significant statistically. 
Mean labour-delivery interval was shorter in vaginal 
group 4.9±2.7 hours versus oral group 6.0±2.2 hours 
(p-0.04). 
 
Table 1:Demographic data of the study 
subjects 
Characteristics Group-A 
Oral (n=50) 
Group-B 
Vaginal (n=50) 
 Mean Standard 
deviation 
Mean Standard 
deviation 
Age (years) 24.8 2.4 25.3 3.1 
Gestational age 
(weeks) 
38.1 1.4 39.7 1.3 
 
Need for Oxytocin augmentation was less in 
vaginal group 21% versus oral group 68 % p-0.009 
(Table – 2). Main indication for intervention was non-
progress of labour and fetal distress. Apgar score at 5 
minutes in group-A and group-B were 8.2±0.83 and 
7.9±0.94 (p-0.119). The incidence of hyper-stimulation 
was similar in both groups. 
There was no difference between the groups 
with respect to mode of delivery and neonatal 
outcome. Caesarean delivery rate was similar in both 
groups p-0.685 (Table – 3). 
Postpartum haemorrhage was not observed in 
any case. No case of uterine rupture or severe birth 
asphyxia was reported. No case of nausea, diarrhoea, 
headache, dizziness and shivering was  noticed. 
 
Table 2:Main outcome measures 
Outcome Group-A 
(n=50) 
Group-B 
(n=50) 
p-
value 
  
Mean 
Standard 
deviation 
 
Mean 
Standard 
deviation 
 
Induction-labour 
interval (hours) 
7.51 4.29 7.31 7.59 0.87 
Labour-delivery 
interval (hours) 
6.00 2.26 4.97 2.75 0.04 
Need of 
Oxytocin 
augmentation 
34 68% 21 42% 0.009 
Apgar score at 5 
minutes 
8.20 0.83 7.92 0.94 0.11 
Uterine 
hyperstimulation 
1 2% 1 2%  
Uterine 
tachysystole 
1 2% 7 14% 0.065 
 
Table 3: Mode of delivery 
Mode of 
delivery 
Group 
Group-A Group-B 
 Pts % Pts % p-value 
SVD with 
Episiotomy 28 56 25 50 0.54 
LSCS 20 40 22 44 0.68 
Outlet Forceps 
delivery 2 4 2 4 -- 
Vacuum 
delivery 0 0 1 2 -- 
Total 50 100 50 100  
 
Discussion 
 
All methods of labour induction not only need 
a careful appraisal of risks and benefits of labour 
outcome, but also require critical assessment of 
possible benefits and morbidity of the fetus.  
Misoprostol has been extensively studied for 
induction of labour through various routes and it has 
proved to be more efficient in stimulating labour 
compared to Oxytocin and Dinoprostin but its dosage 
is not yet licensed because of risk of uterine 
hyperstimulation and its consequences. 5 Several 
studies have been performed in which Misoprostol has 
been used in repeated small doses of 50 µg four to six 
hourly through oral and vaginal routes and has been 
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found safe in induction of labour. 6,7,8 Intracervical 
Misoprostol 50 µg has resulted in 90% success rates in 
other studies regardless of Bishop Score and now 
induction is being tried with greater dosage. 9,10 
This study compares effectiveness and safety 
of 100 µg of Misoprostol through oral and vaginal 
routes. Results show that both the routes are safe and 
effective for induction of labour and can be 
alternatively used. However Misoprostol 100 µg 
through the vaginal route resulted in short induction 
delivery interval and less need of Oxytocin for labour 
augmentation. Same results have been proved by 
Castaneda in his study that 100 µg of vaginal 
Misoprostol resulted in successful cervical ripening 
and short induction delivery interval with acceptable 
safety profile. 10  
In present study there was no significant 
difference between two groups with regard to the 
caesarean section rate, uterine hyperstimulation, 
maternal complications like post partum haemorrhage 
and neonatal outcome. Few cases of tachysystole were 
observed with vaginal route but without any neonatal 
compromise. Similarly Memon in her study used 100 
µg of Misoprostol through the vaginal route for 
induction of labour and proved it to be a safe and 
effective labour inducing agent. 11  
Several studies have proved that initial 50 µg 
of oral Misoprostol is less effective and associated with 
longer induction delivery interval because of first pass 
effect and greater efficiency of vaginal route because of 
greater bioavailability of vaginal Misoprostol. 12 -15   
 
Conclusion 
 
Optimum , oral and vaginal  dose of Misoprostol , for 
induction of labour at term, needs standardization . 
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